Cover Image
市場調查報告書

癲癇藥的全球市場分析:不同治療 (第一代抗癲癇藥,第二代抗癲癇藥,第三代抗癲癇藥),市場區隔預測

Epilepsy Drugs Market Analysis By Treatment (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), And Segment Forecasts To 2024

出版商 Grand View Research, Inc. 商品編碼 368008
出版日期 內容資訊 英文 93 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癲癇藥的全球市場分析:不同治療 (第一代抗癲癇藥,第二代抗癲癇藥,第三代抗癲癇藥),市場區隔預測 Epilepsy Drugs Market Analysis By Treatment (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), And Segment Forecasts To 2024
出版日期: 2016年07月24日 內容資訊: 英文 93 Pages
簡介

本報告提供全球癲癇藥市場相關調查,彙整產業預測,以及不同治療,各地區趨勢,及打入市場的主要企業簡介等資料。

第1章 摘要整理

第2章 市場概要

第3章 市場變動,趨勢,範圍

  • 市場區隔和範圍
  • 市場規模與成長預測
    • 推動市場的要素分析
    • 阻礙市場的要素分析
  • 簡報及成長預測製圖
  • SWOT分析
  • 波特產業分析
  • 市場佔有率/競爭環境

第4章 市場分類1:服務預測與趨勢分析

  • 癲癇藥趨勢分析
  • 第一代抗癲癇藥
  • 第二代抗癲癇藥
  • 第三代抗癲癇

第5章 市場分類2:各地區預測與趨勢分析

  • 各地區市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第6章 競爭環境

  • 策略性架構
  • 市場進入分類
  • 企業簡介
    • Johnson & Johnson
    • UCB Pharma, Inc.
    • Abbott Laboratories, Inc.
    • GlaxoSmithKline PLC
    • Pfizer, Inc.
    • Novartis AG
    • Sanofi Aventis S.A.
    • Shire PLC
    • Cephalon, Inc.
    • Tansna Therapeutics, Inc.

圖表

目錄

The global epilepsy drugs market is expected to reach over USD 5,474.14 million by 2024, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness trainingto the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

Further key findings from the study suggest:

The second generation anti-epileptic drug class is estimated to have over 30% market share in 2015 owing to the high prescription rates, improved tolerability, and increased efficacy due to the novel mechanisms of action of these drugs

The third generation anti-epileptic drug class is expected to witness the fastest growth with a CAGR of over 4% over the forecast period. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.

The growing need to improve the efficacy of the existent drugs and the need to develop new and enhanced anti-epileptic drugs to minimize the associated side-effects, such as dizziness, fatigue, weight gain, and depression are the propelling factors expected to drive the market growth over the forecast period

North America dominated the market in terms of revenue with over USD 2,000 million in 2015 owing to the presence of well-established healthcare infrastructure, favorable government initiatives directed at the betterment of the healthcare system, and the presence of extensive research and development activities

Asia Pacific is expected to witness lucrative growth with a CAGR of around 4.5% over the forecast period owing to the rising disposable income levels and the favorable, healthcare government initiatives in emerging economies, such as India, Japan, and China

Some major players of the epilepsy drugs market include UCB Pharma Ltd., Sanofi S.A, Valeant Pharmaceuticals International, Inc., Pfizer, Inc., Johnson & Johnson, Eisai Co., Ltd., Abbott Laboratories, Inc., Novartis AG, GlaxoSmithKline PLC., Sunovion Pharmaceuticals, Inc., and Cephalon, Inc.

Most of the key players are engaged in strengthening their product portfolio to increase their market share. The introduction of novel drugs is expected to foster the market penetration of anti-epileptic drugs. For instance, in August 2015, the FDA-approved epilepsy tablet, Aptiomby Sunovion Pharmaceuticals, Inc. for people suffering from partial-onset seizures.

Table of Content

Chapter 1: Executive Summary

Chapter 2: Market Snapshot

Chapter 3: Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
  • 3.2 Market size and growth prospects
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Presence of promising pipeline for epilepsy therapeutics
      • 3.2.1.2 Need-gap for adequate seizure control
      • 3.2.1.3 Other drivers
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Cost of treatment
      • 3.2.2.2 Lack of healthcare infrastructure
  • 3.3 Penetration & growth prospect mapping
  • 3.4 Epilepsy Drugs Market - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.5 Industry Analysis - Porter's
  • 3.6 Epilepsy Drugs Market company market share/competitive landscape, 2015

Chapter 4: Market Categorization 1: Epilepsy Drugs Estimates & Trend Analysis

  • 4.1 Epilepsy drugs market: Epilepsy drugs movement analysis
  • 4.2 First Generation Anti-epileptic Drugs
    • 4.2.1 First Generation Anti-epileptic Drugs Market, 2013 - 2024 (USD Million)
  • 4.3 Second Generation Anti-epileptic Drugs
    • 4.3.1 Second generation anti-epileptic drugs market, 2013 - 2024 (USD Million)
  • 4.4 Third Generation Anti-epileptic Drugs
    • 4.4.1 Third generation anti-epileptic drugs market, 2013 - 2024 (USD Million)

Chapter 5: Market Categorization 3: Regional Estimates & Trend Analysis, by Drug

  • 5.1 Epilepsy drugs market share by region, 2015 & 2024
  • 5.2 North America
    • 5.2.1 U.S.
    • 5.2.2 Canada
  • 5.3 Europe
    • 5.3.1 Germany
    • 5.3.2 UK
  • 5.4 Asia Pacific
    • 5.4.1 China
    • 5.4.2 India
  • 5.5 Latin America
    • 5.5.1 Brazil
  • 5.6 MEA
    • 5.6.1 South Africa

Chapter 6: Competitive Landscape

  • 6.1 Strategy framework
  • 6.2 Market participation categorization
  • 6.3 Company Profiles
    • 6.3.1 Johnson & Johnson
      • 6.3.1.1 Company Overview
      • 6.3.1.2 Financial Performance
      • 6.3.1.3 Product Benchmarking
      • 6.3.1.4 Strategic Initiatives
    • 6.3.2 UCB Pharma, Inc.
      • 6.3.2.1 Company Overview
      • 6.3.2.2 Financial Performance
      • 6.3.2.3 Product Benchmarking
      • 6.3.2.4 Strategic Initiatives
    • 6.3.3 Abbott Laboratories, Inc.
      • 6.3.3.1 Company Overview
      • 6.3.3.2 Financial Performance
      • 6.3.3.3 Product Benchmarking
      • 6.3.3.4 Strategic Initiatives
    • 6.3.4 GlaxoSmithKline PLC
      • 6.3.4.1 Company Overview
      • 6.3.4.2 Financial Performance
      • 6.3.4.3 Product Benchmarking
      • 6.3.4.4 Strategic Initiatives
    • 6.3.5 Pfizer, Inc.
      • 6.3.5.1 Company Overview
      • 6.3.5.2 Financial Performance
      • 6.3.5.3 Product Benchmarking
      • 6.3.5.4 Strategic Initiatives
    • 6.3.6 Novartis AG
      • 6.3.6.1 Company Overview
      • 6.3.6.2 Financial Performance
      • 6.3.6.3 Product Benchmarking
      • 6.3.6.4 Strategic Initiatives
    • 6.3.7 Sanofi Aventis S.A.
      • 6.3.7.1 Company Overview
      • 6.3.7.2 Financial Performance
      • 6.3.7.3 Product Benchmarking
      • 6.3.7.4 Strategic Initiatives
    • 6.3.8 Shire PLC
      • 6.3.8.1 Company Overview
      • 6.3.8.2 Financial Performance
      • 6.3.8.3 Product Benchmarking
      • 6.3.8.4 Strategic Initiatives
    • 6.3.9 Cephalon, Inc.
      • 6.3.9.1 Company Overview
      • 6.3.9.2 Financial Performance
      • 6.3.9.3 Product Benchmarking
      • 6.3.9.4 Strategic Initiatives
    • 6.3.10 Tansna Therapeutics, Inc.
      • 6.3.10.1 Company Overview
      • 6.3.10.2 Financial Performance
      • 6.3.10.3 Product Benchmarking
      • 6.3.10.4 Strategic Initiatives

List of Tables

  • TABLE 1: North America epilepsy market, by drug, 2013 - 2024 (USD Million)
  • TABLE 2: U.S. epilepsy market, by drug, 2013 - 2024 (USD Million)
  • TABLE 3: Canada epilepsy market, by drug, 2013 - 2024 (USD Million)
  • TABLE 4: Europe epilepsy market, by drug, 2013 - 2024 (USD Million)
  • TABLE 5: Germany epilepsy market, by drug, 2013 - 2024 (USD Million)
  • TABLE 6: UK epilepsy market, by drug, 2013 - 2024 (USD Million)
  • TABLE 7: Asia Pacific epilepsy market, by drug, 2013 - 2024 (USD Million)
  • TABLE 8: China epilepsy market, by drug, 2013 - 2024 (USD Million)
  • TABLE 9: India epilepsy market, by drug, 2013 - 2024 (USD Million)
  • TABLE 10: Latin America epilepsy market, by drug, 2013 - 2024 (USD Million)
  • TABLE 11: Brazil epilepsy market, by drug, 2013 - 2024 (USD Million)
  • TABLE 12: MEA epilepsy market, by drug, 2013 - 2024 (USD Million)
  • TABLE 13: South Africa epilepsy market, by drug, 2013 - 2024 (USD Million)
Back to Top